ライフサイエンスコーパス: neurofibromatosis type 1

1 e plexiform neurofibroma microenvironment of neurofibromatosis type 1.

2 had prior chemotherapy, and 13 patients had neurofibromatosis type 1.

3 n myeloid malignancies from 10 children with neurofibromatosis type 1.

4 contribute to the neoplastic development of neurofibromatosis type 1.

5 cur sporadically, after radiotherapy, and in neurofibromatosis type 1.

6 d their prognosis related to the presence of neurofibromatosis type 1.

7 major source of morbidity for patients with neurofibromatosis type 1.

8 astatin may prove useful in the treatment of Neurofibromatosis Type 1.

9 ed with tuberous sclerosis complex type 2 or neurofibromatosis type 1.

10 on with the common familial cancer syndrome, neurofibromatosis type 1.

11 a-paraganglioma syndrome and, less commonly, neurofibromatosis type 1.

12 nerve sheath tumors that arise frequently in neurofibromatosis type 1.

13 model to study astrogliosis associated with neurofibromatosis type 1.

14 rowth; inactivating mutations in NF1 lead to neurofibromatosis type 1.

15 their affected parents, in cases of familial neurofibromatosis type 1.

16 ated in leukemic cells in some patients with neurofibromatosis type 1.

17 affected parent of each child with familial neurofibromatosis type 1.

18 strated in leukemic cells from patients with neurofibromatosis type 1.

19 onship to choroidal nodules in patients with neurofibromatosis type 1.

20 s) develop sporadically or in the context of neurofibromatosis type 1.

21 the more common ophthalmic manifestations of neurofibromatosis type 1.

22 of cases, primarily in the optic nerve, with neurofibromatosis type 1.

23 r in association with the inherited syndrome neurofibromatosis type 1.

24 ith a heterozygous mutation of Nf1 linked to neurofibromatosis type 1.

25 e delay observed in patients with IBMPFD and neurofibromatosis type 1.

26 erlie the prevalent familial cancer syndrome neurofibromatosis type 1 [1].

27 (male individuals only 30%; mixed sex 22%), neurofibromatosis type 1 (18%), Down's syndrome (16%), N

28 n in the NF1 tumor suppressor gene underlies Neurofibromatosis type 1, a complex disease that enhance

29 tions in the NF1 tumor suppressor gene cause neurofibromatosis type 1, a pandemic autosomal dominant

30 Although many manifestations of neurofibromatosis type 1 affect the nervous system, othe

31 ing, natural history and how the presence of neurofibromatosis type 1 affects it, unusual presentatio

32 roscopic imaging (MRSI) 9 male subjects with neurofibromatosis type 1 (age, 6-19 years) and 9 age-mat

33 cted pattern of assembly was restored to the neurofibromatosis type 1-Alu template.

34 d, such as Angelman syndrome, Rett syndrome, Neurofibromatosis Type 1 and Fragile X syndrome, the cla

35 arly-phase data suggested that children with neurofibromatosis type 1 and inoperable plexiform neurof

36 PK kinase (MEK) 1 and 2, in children who had neurofibromatosis type 1 and inoperable plexiform neurof

37 ant signaling pathway that is deregulated in neurofibromatosis type 1 and malignant peripheral nerve

38 ed bone marrow samples from 18 children with neurofibromatosis type 1 and myeloid disorders for NF1 m

39 ned the chromosomal abnormalities present in neurofibromatosis type 1 and type 2.

40 manifestations of genetic syndromes such as neurofibromatosis types 1 and 2 or schwannomatosis.

41 ases including tuberous sclerosis complex 2, neurofibromatosis type 1, and Down's syndrome were compa

42 that encompass NF1 cause 5%-10% of cases of neurofibromatosis type 1, and individuals with microdele

43 s a source of dysregulated growth factors in neurofibromatosis type 1, and suggest the further study

44 forms of GIST related to Carney's triad and neurofibromatosis type 1 are discussed in relationship t

45 Tuberous sclerosis and neurofibromatosis type 1 are two pigmentary disorders th

46 Studies of human neurofibromatosis type 1-associated tumors suggest that

47 initially thought to have NS was revised to neurofibromatosis type 1 based on an NF1 nonsense mutati

48 enetics, and cancer screening guidelines for neurofibromatosis type 1, Beckwith-Wiedemann syndrome/ h

49 ular advances in tuberous sclerosis complex, neurofibromatosis type 1, Bloom syndrome, epidermolytic

50 A. beta-catenin modulation in neurofibromatosis type 1 bone repair: therapeutic implic

51 essor NF1 contributes to the pathobiology of neurofibromatosis type 1, but a related role has not bee

52 factor midkine in the skin of patients with neurofibromatosis type 1, but not normal individuals.

53 nd to provide optimum care for patients with neurofibromatosis type 1, clinicians must be aware of th

54 r muscles, lymphedema-distichiasis syndrome, neurofibromatosis type 1, congenital myasthenic syndrome

55 Neurofibromatosis type 1-derived Schwann cells isolated

56 Patients with neurofibromatosis type 1 develop aggressive Schwann cell

57 n (phosphatase with tensin homolog) and Nf1 (neurofibromatosis type 1), enhanced filopodial motility.

58 To test if loss of the neurofibromatosis type 1 gene (Nf1) compromises fibrobla

59 Mutations in the neurofibromatosis type 1 gene predispose patients to dev

60 sms of 22 anonymous markers and 2 within the neurofibromatosis type 1 gene were performed; two-point

61 n H of the factor IX gene and exon 16 of the neurofibromatosis type 1 gene.

62 SCs from neurofibromatosis type-1 gene (Nf1) null mutant mice sho

63 ant myeloid disorders in young children with neurofibromatosis type 1 is 200 to 500 times the normal

64 Neurofibromatosis type 1 is a common autosomal dominant

65 Neurofibromatosis type 1 is a common autosomal dominant

66 Neurofibromatosis type 1 is a relatively common inherite

67 Neurofibromatosis type 1 is a tumor-predisposing genetic

68 Neurofibromatosis type 1 is due to a reduction of the tu

69 A critical event in the pathogenesis of neurofibromatosis type 1 is the heterozygous germ-line l

70 Neurofibromatosis type 1 is the most commonly inherited

71 ately downstream to a T14A11 sequence in the neurofibromatosis type 1 locus.

72 On occasion, neurofibromas in neurofibromatosis type 1 may be present on the lid, brow

73 e, the association of clinical symptoms with neurofibromatosis type 1 might not be appreciated.

74 In neurofibromatosis type 1, molecular assays are being dev

75 ccinate dehydrogenase B-D mutation (n = 21), neurofibromatosis type 1 (n = 1), RET (n = 1), no germli

76 edictors of outcome in patients with/without neurofibromatosis type 1 (NF-1) associated MPNST.

77 In neurofibromatosis type 1 (NF-1), malignant transformatio

78 Five patients (15%) had neurofibromatosis type 1 (NF-1); four of the five patien

79 el-Lindau (VHL) disease (MIM No 199300), and neurofibromatosis type 1 (NF1) (MIM No 162200).

80 in children with refractory solid tumors and neurofibromatosis type 1 (NF1) -related plexiform neurof

81 chwann cell-derived tumors characteristic of neurofibromatosis type 1 (NF1) and in animal models of t

82 Neurofibromatosis type 1 (NF1) and Legius syndrome are r

83 ances in our understanding of the biology of neurofibromatosis type 1 (NF1) and neurofibromatosis typ

84 Multiple tumors are a hallmark of neurofibromatosis type 1 (NF1) and type 2 (NF2) and schw

85 ifferent VA testing methods in children with neurofibromatosis type 1 (NF1) and/or optic pathway glio

86 Children with neurofibromatosis type 1 (NF1) are at increased risk of

87 Children with neurofibromatosis type 1 (NF1) are increasingly recogniz

88 Individuals with neurofibromatosis type 1 (NF1) are predisposed to certai

89 Children with neurofibromatosis type 1 (NF1) are predisposed to juveni

90 Children with neurofibromatosis type 1 (NF1) are predisposed to juveni

91 Children with neurofibromatosis type 1 (NF1) are predisposed to malign

92 Children with neurofibromatosis type 1 (NF1) are prone to learning and

93 th a broad range of signs typically found in neurofibromatosis type 1 (NF1) but no detectable NF1 ger

94 etermine the risk of cancer in patients with neurofibromatosis type 1 (NF1) by cancer type, age, and

95 Children with neurofibromatosis type 1 (NF1) cancer predisposition syn

96 Patients with neurofibromatosis type 1 (NF1) carry approximately a 10%

97 Children with neurofibromatosis type 1 (NF1) carry germline mutations

98 Loss of the tumor suppressor gene NF1 in neurofibromatosis type 1 (NF1) contributes to the develo

99 Patients with neurofibromatosis type 1 (NF1) develop benign plexiform

100 Children with neurofibromatosis type 1 (NF1) develop low-grade brain t

101 The gene responsible for neurofibromatosis type 1 (NF1) encodes a tumor suppresso

102 The gene for neurofibromatosis type 1 (NF1) encodes neurofibromin, a

103 ed by the regionally limited distribution of neurofibromatosis type 1 (NF1) features, has been attrib

104 Individuals with neurofibromatosis type 1 (NF1) frequently exhibit cognit

105 The neurofibromatosis type 1 (Nf1) gene encodes a GTPase act

106 The neurofibromatosis type 1 (NF1) gene encodes the GTPase-a

107 le other patients with JCML show loss of the neurofibromatosis type 1 (NF1) gene, a Ras GTPase activa

108 past decade, since the identification of the neurofibromatosis type 1 (NF1) gene, has witnessed great

109 s a number of different genes, including the neurofibromatosis type 1 (NF1) gene.

110 lin heavy chain (IgH) D segment gene and the neurofibromatosis type 1 (NF1) gene.

111 In this review, we highlight advances in neurofibromatosis type 1 (NF1) genetically engineered mo

112 e imaging for an optic pathway glioma and/or neurofibromatosis type 1 (NF1) had multiple 6 x 6 mm vol

113 A patient with neurofibromatosis type 1 (NF1) had previously been found

114 Individuals with neurofibromatosis type 1 (NF1) have a high incidence of

115 Persons with neurofibromatosis type 1 (NF1) have a predisposition for

116 found that loss of the tumor suppressor gene neurofibromatosis type 1 (Nf1) increased HSF1 levels and

117 from tumor cells, we demonstrate how loss of neurofibromatosis type 1 (NF1) increases RAS-GTP levels

118 mors (pilocytic astrocytomas) arising in the neurofibromatosis type 1 (NF1) inherited cancer predispo

119 Individuals with the neurofibromatosis type 1 (NF1) inherited cancer syndrome

120 Neurofibromatosis type 1 (NF1) is a common autosomal dom

121 Neurofibromatosis type 1 (NF1) is a common autosomal dom

122 Neurofibromatosis type 1 (NF1) is a common autosomal-dom

123 Neurofibromatosis type 1 (NF1) is a common cancer predis

124 Neurofibromatosis type 1 (NF1) is a common genetic disor

125 Neurofibromatosis type 1 (NF1) is a common genetic disor

126 Neurofibromatosis type 1 (NF1) is a common genetic disor

127 Neurofibromatosis type 1 (NF1) is a common genetic disor

128 Neurofibromatosis type 1 (NF1) is a common genetic disor

129 Neurofibromatosis type 1 (NF1) is a common inherited can

130 Neurofibromatosis type 1 (NF1) is a common neurodevelopm

131 Neurofibromatosis type 1 (NF1) is a common neurodevelopm

132 Neurofibromatosis type 1 (NF1) is a common neurogenetic

133 Neurofibromatosis type 1 (NF1) is a common neurogenetic

134 Neurofibromatosis Type 1 (NF1) is a common neurological

135 Neurofibromatosis type 1 (NF1) is a common tumor-predisp

136 Neurofibromatosis type 1 (NF1) is a commonly inherited a

137 Neurofibromatosis type 1 (NF1) is a dominant genetic dis

138 Neurofibromatosis type 1 (NF1) is a dominant genetic dis

139 Neurofibromatosis type 1 (NF1) is a genetic disease caus

140 Neurofibromatosis type 1 (NF1) is a genetic disease that

141 Neurofibromatosis type 1 (NF1) is a genetic disorder res

142 Neurofibromatosis type 1 (NF1) is a prevalent familial c

143 Neurofibromatosis type 1 (NF1) is a prevalent genetic di

144 Neurofibromatosis type 1 (NF1) is among the most common

145 Neurofibromatosis type 1 (NF1) is an autosomal dominant

146 Neurofibromatosis type 1 (NF1) is an autosomal dominant

147 Neurofibromatosis type 1 (NF1) is an inherited disease i

148 The diagnosis of neurofibromatosis type 1 (NF1) is based on 7 clinical cr

149 The human disease neurofibromatosis type 1 (NF1) is caused by mutations in

150 Neurofibromatosis type 1 (NF1) is characterized by cafe-

151 Neurofibromatosis type 1 (NF1) is one of the most common

152 Neurofibromatosis type 1 (NF1) is one of the most preval

153 Neurofibromatosis type 1 (NF1) is the most common form o

154 Neurofibromatosis type 1 (NF1) is the most common geneti

155 Neurofibromatosis type 1 (NF1) is the most common monoge

156 exciting discoveries concerning the basis of neurofibromatosis type 1 (NF1) mental retardation, which

157 Astrocytoma (glioma) formation in neurofibromatosis type 1 (NF1) occurs preferentially alo

158 Neurofibromatosis type 1 (NF1) or von Recklinghausen neu

159 deletions, we have identified a new-mutation neurofibromatosis type 1 (NF1) patient who is somaticall

160 Neurofibromatosis type 1 (NF1) patients are predisposed

161 Neurofibromatosis type 1 (NF1) patients are predisposed

162 Neurofibromatosis type 1 (NF1) patients develop benign n

163 Brains from human neurofibromatosis type 1 (NF1) patients show increased e

164 ival rates and the leading cause of death in neurofibromatosis type 1 (NF1) patients under 40 years o

165 e observation that half of MPNSTs develop in neurofibromatosis type 1 (NF1) patients, subsequent to N

166 ression patterns of optic-pathway gliomas in neurofibromatosis type 1 (NF1) patients.

167 Neurofibromas are common tumors found in neurofibromatosis type 1 (NF1) patients.

168 peripheral nerve sheath tumors (MPNST) from neurofibromatosis type 1 (NF1) patients.

169 Neurofibromatosis type 1 (NF1) predisposes individuals t

170 Neurofibromatosis type 1 (NF1) results from mutations in

171 Neurofibromatosis type 1 (NF1) results from mutations in

172 Vision, quality of life, neurofibromatosis type 1 (NF1) status, and BRAF mutation

173 Neurofibromatosis type 1 (NF1) syndrome is caused by ger

174 roma to a malignant sarcoma in patients with neurofibromatosis type 1 (NF1) syndrome remains unclear.

175 Mutations in the neurofibromatosis type 1 (NF1) tumor suppressor gene are

176 The neurofibromatosis type 1 (NF1) tumor suppressor protein

177 The human neurofibromatosis type 1 (NF1) tumor suppressor protein

178 TOPIC: Children and adults with neurofibromatosis type 1 (NF1), a common autosomal domin

179 Neurofibromatosis type 1 (NF1), a common autosomal domin

180 Children and adults with neurofibromatosis type 1 (NF1), a common autosomal domin

181 Neurofibromatosis type 1 (NF1), a common genetic disorde

182 tions in the NF1 tumor suppressor gene cause neurofibromatosis type 1 (NF1), a common genetic disorde

183 ris) is one of seven diagnostic criteria for neurofibromatosis type 1 (NF1), a common monogenic disor

184 y the NF1 gene, the mutation of which causes Neurofibromatosis type 1 (NF1), a genetic disorder chara

185 metastatic sarcomas that are associated with neurofibromatosis type 1 (NF1), a prominent inherited ge

186 sion profiles in iN cells from patients with neurofibromatosis type 1 (NF1), a single-gene multifacet

187 OPG), seen in 15% to 20% of individuals with neurofibromatosis type 1 (NF1), account for significant

188 Neurofibromatosis type 1 (NF1), an NCFC syndrome, is cau

189 an important ocular finding in patients with neurofibromatosis type 1 (NF1), and early detection of t

190 n, in which loss-of-function mutations cause Neurofibromatosis Type 1 (NF1), contributes to the major

191 In neurofibromatosis type 1 (NF1), deregulation of Ras sign

192 ns in the NF1 tumor-suppressor gene underlie neurofibromatosis type 1 (NF1), in which patients are pr

193 In familial neurofibromatosis type 1 (NF1), individuals with a germ

194 on inherited cancer predisposition syndrome, neurofibromatosis type 1 (NF1), the prevalence of these

195 ging a genetically engineered mouse model of neurofibromatosis type 1 (NF1)-associated optic glioma,

196 omas, OPGs), especially in children with the neurofibromatosis type 1 (NF1)-inherited tumor predispos

197 rments are one of the many manifestations of neurofibromatosis type 1 (NF1).

198 and is mutated in humans with the condition neurofibromatosis type 1 (NF1).

199 As arising sporadically and in patients with neurofibromatosis type 1 (NF1).

200 ect tumor susceptibility in a mouse model of neurofibromatosis type 1 (NF1).

201 ith pseudarthrosis (PA), are associated with neurofibromatosis type 1 (NF1).

202 ed autistic trait burden in individuals with neurofibromatosis type 1 (NF1).

203 are neoplasms that occur in individuals with neurofibromatosis type 1 (NF1).

204 Mutations in NF1 cause neurofibromatosis type 1 (NF1).

205 ation defects are pervasive in patients with neurofibromatosis type 1 (NF1).

206 derived from 13 patients, seven of which had neurofibromatosis type 1 (NF1).

207 have been implicated in the pathogenesis of neurofibromatosis type 1 (NF1).

208 ial model of Schwann cell tumor formation in neurofibromatosis type 1 (NF1).

209 auses substantial morbidity in patients with neurofibromatosis type 1 (NF1).

210 te new treatments for tumors associated with neurofibromatosis type 1 (NF1).

211 kin hyperpigmentation are early hallmarks of neurofibromatosis type 1 (NF1).

212 l feature of the common neurogenetic disease neurofibromatosis type 1 (NF1).

213 benign neurofibromas (BNFs) in patients with neurofibromatosis type 1 (NF1).

214 causing the genetic neurocutaneous disorder neurofibromatosis type 1 (NF1).

215 tions in the NF1 tumor suppressor gene cause Neurofibromatosis type 1 (NF1).

216 ur sporadically in a subset of patients with neurofibromatosis type 1 (NF1).

217 oplasms that commonly occur in patients with neurofibromatosis type 1 (NF1).

218 y-resistant tumours arising in patients with neurofibromatosis type 1 (NF1).

219 ng RAS activity via promoting degradation of neurofibromatosis type 1 (NF1).

220 Individuals with neurofibromatosis type-1 (NF1) can manifest focal skelet

221 oradically or in patients with the inherited neurofibromatosis type-1 (NF1) syndrome.

222 ted tumor predisposition syndrome, including neurofibromatosis types 1 (NF1) and 2 (NF2), familial sc

223 odysplastic syndrome that is associated with neurofibromatosis, type 1 (NF1).

224 Neurofibromatosis type 1 or von Recklinghausen's disease

225 er study of the angiogenic factor midkine in neurofibromatosis type 1 pathogenesis.

226 Neurofibromatosis type 1 patients develop peripheral ner

227 Neurofibromatosis type 1 patients with a submicroscopic

228 Neurofibromatosis type 1 patients with progressive low-g

229 velopment of Schwann cell-derived tumours in neurofibromatosis type 1 patients.

230 mors (MPNST) develop in approximately 10% of neurofibromatosis type-1 patients and are a major contri

231 We report 4 cases of pediatric OPGs (2 neurofibromatosis type 1-related and 2 sporadic cases) t

232 so tested selumetinib using a mouse model of neurofibromatosis type 1-related neurofibroma.

233 l therapies are lacking for the treatment of neurofibromatosis type 1-related plexiform neurofibromas

234 Neurofibromatosis type 1 results from autosomal dominant

235 Segmental neurofibromatosis type 1 (SNF1), characterized by the re

236 years after CRT correlated with patient age, neurofibromatosis type 1 status, tumor location and volu

237 As it is known that children with neurofibromatosis type 1 syndrome have a markedly increa

238 of Nf1, the Ras GTPase gene underlying human neurofibromatosis type 1 syndrome, causes lens dysgenesi

239 at occur sporadically or in association with neurofibromatosis type 1 syndrome.

240 ments in the molecular and biologic bases of neurofibromatosis type 1, tuberous sclerosis, and ectode

241 The neurofibromatosis type 1 tumor suppressor protein neurof

242 th MEN 2B, 1 each with von Hippel-Lindau and neurofibromatosis type 1) underwent adrenalectomy betwee

243 of neurofibromin 1 (Nf1), a gene mutated in neurofibromatosis type 1, unlocked a latent oligodendroc

244 asionally been described in association with neurofibromatosis type 1, whereas an association with ne

245 A patient with neurofibromatosis type 1, which also maps to 17q11.2, an

246 enotype is reminiscent of the human disorder neurofibromatosis type 1, which is characterized by disf

247 ildren with an OPG (sporadic or secondary to neurofibromatosis type 1) who were cooperative for visua